I would like to introduce you to guest
blogger Trevor Soames, a leading Brussels based antitrust lawyer
with extensive experience of major high tech and IP-related investigations and
litigation, having represented several major corporations in various cases over
the years including Qualcomm, Nokia, Samsung and Microsoft.
The Competition Directorate of the
European Commission (DG Comp) has, over the years, become increasingly
interested and active in the field of SEPs.
In a series of cases it has investigated
a variety of potential competition law issues arising from the FRAND
commitment, including allegations of patent ambush in Rambus, the transfer of
FRAND commitments in IPCom,
the risk of supposed “hold up” resulting from SEP holders seeking injunctive
relief in Samsung, and in Motorola, here, and here. In
addition, the European Commission investigated Qualcomm between 2005 and 2009
for, inter alia, alleged excessive pricing regarding its FRAND-committed SEPs.
However, the
case was terminated by the Commission when the four outstanding complaints
were voluntarily withdrawn.
On 21 November 2016, the European
Competition Commissioner, Margarethe Vestager, delivered
a speech which indicated that the she intended to use the competition
law tools at her disposal to deal more aggressively with excessive pricing
cases. She claimed smartphone royalties could be unjustifaibly high. I have already blogged, here,
about her use of a defective aggregate royalty figure in support
of her claims in this speech.
The following article by written by Trevor, and based on what he posted, here,
comments generally on her speech, the policy issues that it raises and the
wrongful identification of SEPs as being a supposed example of excessive
pricing:
"The Opening of the Door: is Excessive
Pricing Control under Article 102 TFEU coming back into vogue
Commentary on Commissioner Vestager’s
speech
Trevor Soames
This short note provides a brief
commentary on the subject of excessive pricing, European Commission enforcement
policy, the examples cited by the Commissioner and what all this may mean for
the application of Article 102 TFEU.
Excessive pricing control under Article
102 TFEU has been a fraught subject ever since the United Brands judgment of the CJEU. For our US cousins, the very
idea that antitrust law could apply to excessive pricing must seem more than
passing strange. The Supreme Court made
its views on the subject very clear in Justice Scalia’s Trinko opinion where he argued that the "mere possession of monopoly power, and the concomitant charging of monopoly prices, is not only
not unlawful; it is an important element of the free-market system. The
opportunity to charge monopoly prices – at least for a short period – is what attracts
'business acumen' in the first place; it induces risk taking that produces
innovation and economic growth”.
The European Commission, to its
great credit, has exercised great restraint in applying Article 102 TFEU in
this area. A critical step in this
process of increasing self-restraint was the adoption of the two Helsingborg complaint rejection decisions
in 2014 which, unusually for such decisions, made a finding not merely that
there was no Community interest in investigating the case further but rather,
and more strongly, that there was “insufficient evidence to conclude that the
prices charged…are unfair/excessive and thus constitute an abuse within the
meaning of article 82 of the Treaty”. The decisions are worth (re-) reading,
see this and this.
Since that time there have been
very few cases of excessive pricing at EU level. Except for a handful of exceptional cases,
those which have been investigated as such have been terminated by the Commission
without findings of infringement.
The European Commission
emphasised its cautious and restrained approach to the application of Article
102 TFEU to alleged excessive pricing in its written submission to the OECD of
7 October 2011. The paper provides a useful summary of its enforcement policy,
the rationale behind its emphasis on exclusionary practices and the problems
that would be encountered in taking on excessive pricing cases. Given that this subject has raised its head
again, re-reading this carefully written paper is well worthwhile. The position was well summarised at para. 42,
as follows:
“It
seems that enforcement action against excessive prices has only been considered
as a last resort, in markets where high prices and high profits do not have
their usual signalling function to attract entry and expansion because of very
high and long lasting barriers to entry and expansion. This recognises that
even though in many markets prices may be temporarily high, due to a mismatch
of demand and supply or the exercise of market power, it is preferable to give
market forces the time to play out and entry and expansion to take place,
thereby bringing prices back to more normal levels. We have not seen
enforcement activity in such markets, recognising that it would be unwise to
run the risk of taking a wrong decision and furthermore spend enforcement
resources on solving a problem that would solve itself over time anyway. This
is so even in markets characterised by sufficient entry barriers where there
can be dominant firms. Of course, it may be that a dominant firm tries to
prevent this process of entry and expansion taking place by artificially
raising entry barriers. However, in such a situation it is more efficient for
the competition authority to tackle the raising of these entry barriers
directly since this will likely amount to an exclusionary abuse. If, however,
the market is characterized by such entry barriers that it is unlikely that
market forces over time will bring prices down, enforcement actions aimed
directly against excessive prices may indeed be appropriate.”
We have seen, however, a greater
willingness by some member states with less self-control than the Commission to
develop cases in this area. We have also
seen other non-EU competition jurisdictions which look to the EU for
inspiration in the area of dominance control seeking to utilise their domestic
Article 102 equivalents to attack what they see as excessive pricing or unfair
terms. Some of these cases have been
notorious in terms of the intellectual contortions and use (sometimes misuse) of
EU case law relied on to reach their conclusions.
Although the Commissioner
identified a few limits to the application of excessive pricing control, she
gave a clear message. Namely, that the
European Commission is open for business in this area in a manner not seen for
many years. In response to my question,
she confirmed that a door which had been almost closed has now been opened, at
least to some degree. She said “...we’re
still bound to come across cases where competition hasn’t been enough to
provide a real choice. Where dominant businesses are exploiting their
customers, by charging excessive prices or imposing unfair terms”. Rightly, she emphasised caution saying that “we
have to be careful in the way we deal with those situations. Because sometimes, a company is dominant simply because it’s better
than its competitors. And when that’s the case, it’s only fair that it should
get the rewards of its efforts. But we also need to be
careful that we don’t end up with competition authorities taking the place of
the market. The last thing we should be doing is to set ourselves up as a
regulator, deciding on the right price”.
However, “there can still be
times when we need to intervene”. In
closing the Commissioner said that “we need to act carefully when we deal with
excessive prices. The best defence against exploitation remains the ability to
walk away. So, we can often protect consumers just by stopping powerful
companies from driving their rivals out of the market. But we still have the option
of acting directly against excessive prices. Because we have a
responsibility to the public. And we should be willing to use every means we
have to fulfil that responsibility”.
For me, it is those last two
sentences that gave some cause for concern and indicated that the door was
being opened, as was indeed confirmed.
Now, it is true, that the
Commissioner stated that excessive pricing control should only be used where
there is no ability for the customer/consumer to “walk away”. The product or
service being charged for does not need to be an essential facility in the
manner normally used, namely whether access to the deemed essential facility is
denied to a competitor, or is granted only on discriminatory terms, but rather
whether the customer/consumer has a choice (note that the Commissioner didn’t
use the essential facility concept, the application of which has been limited
after the Oscar Bronner case). Furthermore, the Commissioner says that
although there may be future cases where alleged excessive pricing may be
investigated and, indeed, decided upon, the Commission would not be a price
regulator and would not decide on “the right price”. That is all very well and it sounds
comforting, but what it really means is that the Commission would merely decide
that the price charged was unlawful, explain the grounds on which it so held
and no doubt order that the price be adjusted so that it was reasonable. Little
guidance may be provided by the Commission as to what it considers reasonable
in the particular circumstances and if the allegedly dominant company gets its
pricing wrong, it will be fined for having failed to comply with the
Commission’s order without being able to seek clarity from a Court. So, although the Commission would indeed not
“set” the price, its actions would undoubtedly change the pricing levels set
and the impugned and allegedly company would need to be cautious. De facto the Commission will therefore
be a price regulator, whatever it may claim.
Let us turn (briefly) to the
three examples of excessive pricing identified by the Commissioner, Gazprom,
pharmaceuticals and Standard Essential Patents (SEPs):
- Gazprom: this is not a pure excessive pricing case at all and
seems a strange example to choose. The
Commission’s allegations revolve around a series of exclusionary behaviours,
territorial restrictions and market partitioning including export bans,
destination clauses and measures that prevent the cross-border flow of gas, the
combination of which has resulted in higher gas prices and the segmentation of
gas markets along national borders.
- Pharmaceuticals:
the Commissioner seemed to be focussed on a number of examples of off-patent
drugs having been subject to significant price increases. A notorious example was the 5,000% price
increase implemented by Turing Pharmaceuticals and its CEO Martin Shkreli for Daraprim,
a 62 year old medication. In addition there have been a number of NCA
investigations as referred to by the Commissioner, including the recent Article
102 TFEU decision of the UK CMA regarding alleged excessive pricing for
phenytoin sodium capsules (Pfizer/Flynn).
These cases warrant a lengthier discussion than is possible in this note, but
there are special circumstances at play in the pharmaceutical sector due to Government
imposed price regulation that create a somewhat unique environment within which
competition law operates. One might have
thought, along the lines of Justice Scalia’s reasoning in Trinko, that an off-patent drug which is subject to a substantial
price increase would incentivise new entrants to generate competitive
alternatives. This would be consistent
with para. 61 of the European Commission’s 2011 OECD paper where it stated that
“enforcement
against excessive prices is generally only contemplated in markets with an
entrenched dominant position where entry and expansion of competitors cannot be
expected to ensure effective competition in the foreseeable future, that is
markets where high prices and high profits do not have their usual signalling
function to attract entry and expansion.”
- SEPs:
this is yet another strange example to have been included in the Commissioner’s
list as it relates to an alleged phenomenon (royalty stacking and hold-up) for
which there is no evidence at all. Unlike
the Gazprom and pharmaceutical examples cited by the Commissioner, the claimed
phenomenon is entirely hypothetical and there is no empirical evidence that
shows or proves that it exists. The
speech claims that a recent study “shows that 120 dollars of the cost of each
smartphone comes from paying royalties for the patents it contains.” This is untrue. The
study cited by the Commissioner is based on a purely hypothetical
analysis as its authors themselves said when they caveated the report by
stating that “we estimate
potential patent royalties in excess of $120 on a hypothetical $400 smartphone.” Even Professor Carl Shapiro, one of
the leading proponents of the royalty stacking and hold up theory was unable in
his 2015 IEEE paper to provide any such evidence, see the note
I posted on this subject, here.
There are multiple recent studies on this subject that elaborate on the utter
and complete absence of any empirical evidence and, indeed, in the case of one
important paper by Padilla and Llobet on “The Inverse Cournot Effect in
Royalty Negotiations with Complementary Patents” seeks to
explain, in a rigorous manner, why royalty stacking is not observed in real, as
opposed to hypothetical, life. In other words, the Commissioner’s SEP example of
alleged excessive pricing is no example at all.
In conclusion, I cannot recall a Competition
Commissioner’s speech on excessive pricing in recent times. It was clearly delivered for a purpose and as
the Commissioner confirmed it would seem that “a door which was almost closed”
has now been opened “a little”. But what
does that mean? Some of the statements
made, as well as examples used, give cause for concern. We will have to wait and see how this policy
initiative develops, both at the Commission and at member state level. My sense is that there is a greater potential
for investigation and intervention in this area than for many years and a
political willingness to go into territory only rarely entered into previously.
© Trevor Soames
Avocat au Barreau de Bruxelles
Solicitor-Advocate & Barrister"